Atherosclerosis Treatment Drugs
Market - Driver
Increasing number of pipeline
studies and rising involvement of key players for developing the treatment
options for atherosclerosis are expected to propel Atherosclerosis
Treatment Drugs Market growth. For Instance, in November 13, 2018, Bayer in
collaboration with Janssen, LP started the clinical study for Rivaroxaban and
Acetylsalicylic Acid to build up the insights in treatment patterns and to
study results of Rivaroxaban (Xarelto) in combination with acetylsalicylic acid
(xatoa) prescribed to patients with atherosclerosis. The study is estimated to
complete in August 2021.
Moreover, technological
advancement in the atherosclerosis treatment procedures is expected to boost
the atherosclerosis treatments drug market growth. For instance, in May 2017,
Researchers at Ben-Gurion University (BGU) and the Sheba Medical Center
developed Nano polymer therapy, a new therapy for the treatment of
atherosclerosis. It prevents heart failure with a new biomedical polymer
(E-selectin-targeting polymer) that reduces arterial plaque and inflammation in
the cardiovascular system. E-selectin-targeting polymer helps to reduce
existing plaque and impedes the further plaque formation. It also prevents
arterial thrombosis, ischemia, myocardial infarction, and strokes.
Atherosclerosis is characterized
by the narrowing and hardening of the arteries. In this condition, arteries
become blocked by fatty substances, such as cholesterol. These substances are
called as plaques or atheroma. The risks of atherosclerosis increase with age.
The deposition of plaque tends to narrow the arterial canal, which result in
the limited flow of blood and oxygen through it. Atherosclerosis commences with
damage to the endothelium of arteries leading to the formation of plaque. This
condition is dangerous for the vital organs such as heart and brain.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2430
The risk associated with
atherosclerosis includes serious cardiovascular and brain diseases.
Collectively, these conditions are more common for cardiovascular diseases
(CVD) including coronary heart disease, angina pectoris, and transitory
ischemia. Other risks for atherosclerosis are carotid artery disease, kidney
disease, and peripheral artery disease.
Atherosclerosis Treatment Drugs
Market- Restraints
However, the side effects
associated with atherosclerosis drugs and limited efficacy of the drugs is
expected to hamper atherosclerosis market growth. For instance, in November
2016, The Lancet led by Rory Collins, provided an evidence on statin therapy
and the methodological limitations. As per data, statins are associated with
increased incidence of diabetes and hemorrhagic stroke. Statins tends to increase
the risk of type 2 diabetes in a dose-dependent mode.
Atherosclerosis Treatment Drugs
Market- Regional Analysis
On the basis of region, the
global atherosclerosis treatment drugs market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/atherosclerosis-treatment-drugs-market-2430
Geographically, North America is
expected to gain significant market share over the forecast period, owing to
increasing incidences of atherosclerotic condition among the population in this
region. For instance, in November 2016, as per data provided by the U.S.
Centers for Disease Control and Prevention (CDC) and the World Health
Organization (WHO), there were more than 15.5 million Americans who had
coronary artery disease and it is expected that for every 42 seconds an American
will experience the onset of a myocardial infarction.
Furthermore, Asia Pacific is
expected to witness significant growth in the market, owing to expansion of
major key players in this region. For instance, in October 2017, GSK opened its
new regional headquarters for Asia in Singapore. The GSK’s purpose for building
headquarters is to support the pharmaceutical, vaccines, and consumer
healthcare businesses across multiple regions in Asia Pacific.
Key players operating in the
Atherosclerosis treatment drugs market include GlaxoSmithKline plc. Merck &
Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Anthera
Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The
Medicine Company, and Cardium Therapeutics.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2430
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment